BEng, MBBS, Neurology Registrar, Sunshine Coast University Hospital, Birtinya, Qld.
BPharm (Hons), MBBS, FRACP, Staff Neurologist, Sunshine Coast University Hospital, Birtinya, Qld.
Aust J Gen Pract. 2022 Apr;51(4):199-206. doi: 10.31128/AJGP-07-21-6103.
Multiple sclerosis (MS) is a multifocal inflammatory central nervous system disorder. There are now many highly effective disease-modifying therapies (DMTs) available as treatment options, which have a significant impact on disease activity and long-term disability.
The aim of this article is to provide a concise overview of the diagnosis, DMTs and prognosis of MS.
The diagnosis of MS is made on clinicoradiological grounds to prove dissemination of disease in both time and space in the nervous system. While the expanding options of DMTs have had a significant impact on disability, they make medication selection for individual patients more complicated. Patients with MS often have a model of care shared between the neurologist and the general practitioner. This review article summarises the key aspects of the diagnosis, DMTs and prognosis of MS relevant to the general practitioner.
多发性硬化症(MS)是一种多灶性炎症性中枢神经系统疾病。现在有许多高效的疾病修正治疗药物(DMTs)可供作为治疗选择,这些治疗选择对疾病活动度和长期残疾有显著影响。
本文旨在对 MS 的诊断、DMTs 和预后提供简明概述。
MS 的诊断是基于临床和影像学依据,以证明神经系统中疾病在时间和空间上的扩散。虽然 DMTs 的不断扩展选择对残疾有显著影响,但它们使为个别患者选择药物变得更加复杂。MS 患者通常有一个由神经科医生和全科医生共同管理的护理模式。这篇综述文章总结了与全科医生相关的 MS 诊断、DMTs 和预后的关键方面。